Disulfiram (DSF), an established alcohol-aversion drug, is a candidate for repurposing in cancer treatment. DSF's antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced-stage cancer patients encounter variable results. Here, we show that one reason for the inconsistent clinical effects of DSF may reflect interference by other drugs. Using a high-throughput screening and automated microscopy, we identify cannabidiol, an abundant component of the marijuana plant used by cancer patients to mitigate side effects of chemotherapy, as a likely cause of resistance to DSF. Mechanistically, in cancer cells, cannabidiol triggers the expression of metallothioneins providing protective effects by binding heavy metal-based substances including the bis-diethyldithiocarbamate-copper complex (CuET). CuET is the documented anticancer metabolite of DSF, and we show here that the CuET's anticancer toxicity is effectively neutralized by metallothioneins. Overall, this work highlights an example of undesirable interference between cancer therapy and the concomitant usage of marijuana products. In contrast, we report that insufficiency of metallothioneins sensitizes cancer cells toward CuET, suggesting a potential predictive biomarker for DSF repurposing in oncology.

Danish Cancer Society Research Center Copenhagen Denmark

Division of Genome Biology Department of Medical Biochemistry and Biophysics Science for Life Laboratory Karolinska Institute Stockholm Sweden

Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Brar SS, Grigg C, Wilson KS, Holder WD, Dreau D, Austin C, Foster M, Ghio AJ, Whorton AR et al. (2004) Disulfiram inhibits activating transcription factor/cyclic AMP‐responsive element binding protein and human melanoma growth in a metal‐dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 3, 1049–1060. PubMed

Chen D, Cui QC, Yang H & Dou QP (2006) Disulfiram, a clinically used anti‐alcoholism drug and copper‐binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66, 10425–10433. PubMed

Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, Jung JM & Oberling F (1993) Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy 6, 9–12. PubMed

Karamanakos PN, Trafalis DT, Papachristou DJ, Panteli ES, Papavasilopoulou M, Karatzas A, Kardamakis D, Nasioulas G & Marselos M (2017) Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme ‐ A propos of a case. J BUON 22, 1227–1232. PubMed

Lewison EF (1976) Spontaneous regression of breast cancer. Natl Cancer Inst Monogr 44, 23–26. PubMed

Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S et al. (2019) A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide‐resistant glioblastoma. J Neurooncol 142, 537–544. PubMed

Tran AA & Prasad V (2020) Drug repurposing for cancer treatments: a well‐intentioned, but misguided strategy. Lancet Oncol 21, 1134–1136. PubMed

Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC & Kim AH (2018) Final results of a phase I dose‐escalation, dose‐expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol 138, 105–111. PubMed

Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, Nisman B, Peretz T & Peylan‐Ramu N (2015) A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non‐small cell lung cancer. Oncologist 20, 366–367. PubMed PMC

Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z et al. (2017) Alcohol‐abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194–199. PubMed PMC

Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M & Bartek J (2019) Disulfiram’s anti‐cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. Oncogene 38, 6711–6722. PubMed

Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S & Corsi L. (2018) Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int 2018, 1691428. PubMed PMC

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH & Abílio VC (2018) Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol 9, 482. PubMed PMC

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC et al. (2017) Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 175, 133–150. PubMed

Massi P, Solinas M, Cinquina V & Parolaro D (2013) Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 75, 303–312. PubMed PMC

Mortimer TL, Mabin T & Engelbrecht A‐M (2019) Cannabinoids: the lows and the highs of chemotherapy‐induced nausea and vomiting. Future Oncol 15, 1035–1049. PubMed

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K et al. (2015) Cannabinoids for medical use: a systematic review and meta‐analysis. JAMA 313, 2456–2473. PubMed

Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P & Parolaro D (2006) The non‐psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 63, 2057–2066. PubMed PMC

Freimuth N, Ramer R & Hinz B (2010) Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332, 336–344. PubMed

Chung U, Seo J‐S, Kim Y‐H, Son GH & Hwang J‐J (2012) Quantitative analyses of postmortem heat shock protein mRNA profiles in the occipital lobes of human cerebral cortices: implications in cause of death. Mol Cells 34, 473–480. PubMed PMC

Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP et al. (2013) The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ 20, 1485–1497. PubMed PMC

Chen W, Yang W, Chen P, Huang Y & Li F (2018) Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug‐resistant prostate cancers. ACS Appl Mater Interfaces 10, 41118–41128. PubMed

Koturbash I & MacKay D (2020) Cannabidiol and other cannabinoids: from toxicology and pharmacology to the development of a regulatory pathway. J Diet Suppl 17, 487–492. PubMed

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G, Geschwind D & Vogel Z (2012) Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9‐tetrahydrocannabinol in BV‐2 microglial cells. Br J Pharmacol 165, 2512–2528. PubMed PMC

Scott KA, Dennis JL, Dalgleish AG & Liu WM (2015) Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Res 35, 5827–5837. PubMed

Juknat A, Rimmerman N, Levy R, Vogel Z & Kozela E (2012) Cannabidiol affects the expression of genes involved in zinc homeostasis in BV‐2 microglial cells. Neurochem Int 61, 923–930. PubMed

Foster AW & Robinson NJ (2011) Promiscuity and preferences of metallothioneins: the cell rules. BMC Biol 9, 25. PubMed PMC

Coyle P, Philcox JC, Carey LC & Rofe AM (2002) Metallothionein: the multipurpose protein. Cell Mol Life Sci 59, 627–647. PubMed PMC

Radtke F, Heuchel R, Georgiev O, Hergersberg M, Gariglio M, Dembic Z & Schaffner W (1993) Cloned transcription factor MTF‐1 activates the mouse metallothionein I promoter. EMBO J 12, 1355–1362. PubMed PMC

Meraz‐Torres F, Plöger S, Garbe C, Niessner H & Sinnberg T (2020) Disulfiram as a therapeutic agent for metastatic malignant melanoma—old myth or new logos? Cancers 12, 3538. PubMed PMC

Casini A, Karotki A, Gabbiani C, Rugi F, Vašák M, Messori L & Dyson PJ (2009) Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein‐2: relevance to the mechanism of action. Metallomics 1, 434–441. PubMed

Merlos Rodrigo MA, Jimenez Jimemez AM, Haddad Y, Bodoor K, Adam P, Krizkova S, Heger Z & Adam V (2020) Metallothionein isoforms as double agents ‐ Their roles in carcinogenesis, cancer progression and chemoresistance. Drug Resist Updat 52, 100691. PubMed

Wong DL & Stillman MJ (2018) Capturing platinum in cisplatin: kinetic reactions with recombinant human apo‐metallothionein 1a. Metallomics 10, 713–721. PubMed

Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T & Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51, 3237–3242. PubMed

Mangelinck A, da Costa MEM, Stefanovska B, Bawa O, Polrot M, Gaspar N & Fromigué O (2019) MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma. Sci Rep 9, 12301. PubMed PMC

Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, Humeidi R, Peck D, Wu X et al. (2020) Discovering the anti‐cancer potential of non‐oncology drugs by systematic viability profiling. Nat Cancer 1, 235–248. PubMed PMC

Brewer GJ, Hill GM, Prasad AS, Cossack ZT & Rabbani P (1983) Oral zinc therapy for Wilson’s disease. Ann Intern Med 99, 314–319. PubMed

Halfdanarson TR, Kumar N, Hogan WJ & Murray JA (2009) Copper deficiency in celiac disease. J Clin Gastroenterol 43, 162–164. PubMed

Krizkova S, Ryvolova M, Hrabeta J, Adam V, Stiborova M, Eckschlager T & Kizek R (2012) Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev 44, 287–301. PubMed

Shi Y, Amin K, Sato BG, Samuelsson SJ, Sambucetti L, Haroon ZA, Laderoute K & Murphy BJ (2010) The metal‐responsive transcription factor‐1 protein is elevated in human tumors. Cancer Biol Ther 9, 469–476. PubMed PMC

Si M & Lang J (2018) The roles of metallothioneins in carcinogenesis. J Hematol Oncol 11, 107. PubMed PMC

Jung AY, Cai X, Thoene K, Obi N, Jaskulski S, Behrens S, Flesch‐Janys D & Chang‐Claude J (2019) Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy. Am J Clin Nutr 109, 69–78. PubMed

Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET

Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics